Peptide API supplier for the USA: sourcing from India, step by step

Who buys peptides from India, and what each needs

The requirements depend on what the peptide will be used for. Once a peptide becomes the active ingredient of a drug or of a clinical-trial product, the CGMP and FDA filing chain described below applies. For laboratory research it does not, but the buyer still needs reliable identity, purity and documentation.

Buyer	Typical use	Grade	Key requirements
Pharmaceutical manufacturers and generic developers	API for an ANDA or NDA product, and development batches for the application	GMP API	CGMP to ICH Q7, FDA registration and listing, Type II DMF and letter of authorisation (covered in this guide)
Biotech and drug-development companies	Investigational new drugs for clinical trials	GMP API	IND under 21 CFR Part 312 and CGMP appropriate to the phase (FDA guidance on CGMP for Phase 1 investigational drugs)
CDMOs, CMOs and fill-finish companies	API sourced for a client’s product, or a client’s API taken into vials	GMP API or client-supplied	The client’s specification and a written quality agreement (FDA guidance on contract manufacturing quality agreements)
Animal drug manufacturers	Active ingredient of an animal drug	GMP API	Regulated by FDA’s Center for Veterinary Medicine; CGMP and establishment registration also apply
Universities, hospital and biomedical research institutes	In-vitro and preclinical laboratory research	Research grade (RUO)	Certificate of analysis with identity (mass spectrometry) and purity (HPLC), counter-ion and peptide content where needed, and an end-use statement
CROs and analytical laboratories	Method development, impurity identification, in-house working standards	Research grade or custom	Full characterisation data; official reference standards still come from USP
Diagnostics and assay developers	Peptides as antigens, calibrators or controls	Research grade or custom	Supplier qualification by the device maker; research-phase IVD products are labelled “For Research Use Only. Not for use in diagnostic procedures.” (21 CFR 809.10(c))
Research-peptide brands and distributors	Resale to laboratories, often in lyophilised vials	Research grade (RUO)	Batch certificates of analysis, “research use only, not for human or veterinary use” labelling, and no promotion for human use, which FDA treats as drug marketing

Research-grade material cannot be upgraded later: a peptide bought for laboratory research cannot become the API of a drug or a clinical-trial product. Tell us the end use in your first enquiry so we quote the right grade and documents.

What a US pharmaceutical buyer needs in place

In the US, responsibility for the API sits with the applicant whose ANDA or NDA uses it, but several obligations fall directly on the foreign manufacturer. All of them need to be in place before FDA will accept the API in an application.

Requirement	Basis	Who holds it	What to ask the supplier for
CGMP for API manufacture	FD&C Act §501(a)(2)(B); ICH Q7 (FDA guidance, 2016)	API manufacturer	Quality system overview, inspection history, audit access
Establishment registration and drug listing	21 CFR Part 207	API manufacturer, through a US agent	Registration and listing details, US agent contact
Chemistry, manufacturing and controls data	21 CFR 314.420 (Type II DMF), or data in the application	DMF holder; referenced by the applicant	DMF number, completeness-assessment status, letter of authorisation
Supplier qualification and incoming testing	21 CFR Part 211 (finished-product CGMP, §211.84)	Applicant / finished-product manufacturer	Certificates of Analysis, method transfer support, audit access

Type II Drug Master Files

A Type II DMF holds confidential information on a drug substance, its intermediates and the materials used to make them. Under 21 CFR 314.420, FDA “ordinarily neither independently reviews drug master files nor approves or disapproves submissions to a drug master file”. The DMF is reviewed when an application references it, using a letter of authorisation from the holder. FDA’s own guidance page adds that DMFs are not required by statute or regulation: an applicant can include the API data directly instead, but most API manufacturers use a DMF to keep process details confidential.

For generic applications, the Generic Drug User Fee Amendments (GDUFA) add two steps. The DMF holder pays a one-time DMF fee, $109,899 for fiscal year 2027 (1 October 2026 to 30 September 2027), and FDA runs a completeness assessment. DMFs that pass are published on FDA’s list as available for reference. Under GDUFA III, FDA can also begin an early assessment of a Type II API DMF up to six months before an ANDA is submitted.

The public list is also a market signal. FDA’s current DMF list shows 95 active Type II DMFs whose subject names semaglutide, covering the drug substance, process variants and intermediates. Being listed is not an FDA quality endorsement; it means the file exists and is active.

CGMP: ICH Q7 for API manufacturing

A drug, including an API, is adulterated under section 501(a)(2)(B) of the FD&C Act if it is not made in conformity with current good manufacturing practice. FDA does not have API-specific CGMP regulations; it uses ICH Q7, issued as FDA guidance in September 2016, as its expectation for API manufacture. ICH Q7 covers APIs made by chemical synthesis, extraction, cell culture or fermentation, so it applies to synthetic peptides.

The applicant’s finished-product site then qualifies the supplier under 21 CFR Part 211. Section 211.84 allows a Certificate of Analysis to replace full incoming testing only if at least one specific identity test is performed and the reliability of the supplier’s results is established and periodically checked.

Peptide ANDAs after July 2026

The reference semaglutide injection product is made from a peptide backbone “produced by yeast fermentation” and then chemically modified, according to its prescribing information. Generic versions can be recombinant, synthetic or semi-synthetic, which is why FDA’s guidance on impurities matters so much to API choice.

In May 2021, FDA issued guidance on ANDAs for certain highly purified synthetic peptides that refer to listed drugs of rDNA origin. It named glucagon, liraglutide, nesiritide, teriparatide and teduglutide; new impurities above 0.5% were not acceptable, and those between 0.10% and 0.5% had to be identified, characterised and justified, including through comparative immunogenicity risk assessment.

On 28 July 2026, FDA withdrew that guidance because it “no longer reflects FDA’s current scientific thinking”, published 17 revised draft product-specific guidances (PSGs), and said it plans to revise the general guidance. The revised draft PSG for semaglutide injection (RLD NDA 209637) applies to recombinant, synthetic and semi-synthetic product:

Element	Draft PSG recommendation (July 2026)
Reporting	Report active-ingredient-related impurities above 0.1% of the drug substance
Identification	Identify impurities above 0.5%
Impurities common with the RLD	Not greater than the RLD level or 1.0%, whichever is greater
New impurities	Efforts should be made to reduce them below 1.0%
Total impurities	Not greater than the RLD; all impurities above 0.1% summed
Higher levels	Do not preclude an ANDA, but are subject to scientific review and justification

The PSG also recommends comparative characterisation to support active-ingredient sameness and assessment of aggregates and non-peptide impurities as part of the immunogenicity evaluation. For the analytical side, see peptide API impurities and specifications.

Registration, listing and import

• Registration: under 21 CFR 207.17, every foreign establishment that manufactures a drug imported or offered for import into the US must register with FDA.
• US agent: 21 CFR 207.69(b) requires a foreign registrant to designate a single US agent, who must be physically present in the US and helps FDA schedule inspections.
• Annual update and listing: registration is renewed each year between 1 October and 31 December (207.29), and products are listed under 207.41, electronically through eDRLS.
• Import: FDA screens drug entries through its import program and can examine, detain or refuse shipments. Prior notice under 21 CFR 1.277 applies to food, not drugs.

Semaglutide in the US: the patent timeline

FDA’s Orange Book lists US patent 8,129,343 for semaglutide, covering the drug substance and product, with an expiry of 5 December 2031. Novo Nordisk reports US compound patent expiry as 2032. Novo Nordisk has settled patent litigation with several ANDA filers on confidential terms, so no public early-entry date is available. Development work and the generation of data for FDA submissions fall under the safe harbour of 35 U.S.C. 271(e)(1); commercial launch is a separate question for your patent counsel. Our article on semaglutide patent expiry by country compares markets.

Where Winhycare Pharma fits

• Peptide APIs: Semaglutide, Tirzepatide, Retatrutide, Cagrilintide and BPC-157, supplied B2B to licensed pharmaceutical manufacturers and developers with a Certificate of Analysis, and US-DMF / CTD Module 3 documentation support for Semaglutide.
• Peptide CRDMO services: process and analytical development and technology transfer for your own peptide programme.
• Peptide lyophilisation and vial filling: peptides and biosimilars lyophilised and filled into vials through our manufacturing partner, starting with engineering or pilot batches.
• Research peptides and custom peptide synthesis: 16 research peptides at >99% purity and custom sequences for universities, research institutes, CROs, diagnostics developers and distributors, supplied for research use only and not as GMP API.

We will tell you plainly which documents exist today for your molecule and target market, and which would need to be generated, before you commit to an audit. Peptide APIs are supplied to licensed manufacturers and developers. Research-grade peptides are supplied for research use only and cannot be qualified as the active substance of a medicinal product.

How to start

1. Send an enquiry with the molecule, quantity, intended use (laboratory research, development, clinical or commercial) and the documents your quality or regulatory team needs.
2. Sign a mutual NDA.
3. Review technical and quality documentation and complete your supplier questionnaire.
4. Evaluate samples, or run a pilot for lyophilisation projects.
5. Audit the site with your QA team or a contracted auditor.
6. Agree the quality agreement and supply terms.